



Rexahn Pharmaceuticals, Inc.  
Investor Relations Department  
15245 Shady Grove Road, Suite  
455  
Rockville, MD 20850  
United States

Visit IR website [↗](#)  
Sign-up for email alerts [↗](#)

**AMEX: RNN**

Last Trade:	2.16
Trade Time:	3:59 PM ET 05/24/18
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	1.42 - 4.37
Volume	N/A

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing best-in-class therapeutics for the treatment of cancer. Rexahn currently has two clinical stage oncology candidates, RX-3117 and RX-5902 (Supinoxin™), and additional compounds in preclinical development to treat multiple types of cancer.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- 05/15/18**  
[Rexahn Phase 2a Combination Study of RX-3117 and Abraxane® in First-line Metastatic Pancreatic Cancer Patients Advances to Second Stage](#)
- 05/07/18**  
[Rexahn Reports First Quarter 2018 Financial Results](#)
- 04/26/18**  
[Rexahn to Present Clinical Data at 2018 American Society of Clinical Oncology \(ASCO\) Annual Meeting](#)
- 03/13/18**  
[Rexahn Pharmaceuticals to Present at Two Upcoming Conferences](#)
- 03/12/18**  
[Rexahn Pharmaceuticals Reports Full Year 2017 Financial Results](#)

## Financials [\[ View all \]](#)

- [First Quarter Financial Results](#)
- 03/09/18**  
[Annual Report \(10-K\)](#)
- 04/23/18**  
[Proxy Statement \(DEF 14A\)](#)
- 05/04/18**  
[Quarterly Report \(10-Q\)](#)
- 11/03/17**  
[Quarterly Report \(10-Q\)](#)
- 08/04/17**  
[Quarterly Report \(10-Q\)](#)